The Journal of Urology
Volume 183, Issue 6 , Pages 2128-2136 , June 2010

Urological Surgery and Antiplatelet Drugs After Cardiac and Cerebrovascular Accidents

  • Daniel Eberli

      Affiliations

    • Urology Clinic, University Hospital Zürich, Zürich, Switzerland
    • Corresponding Author InformationCorrespondence: Urology Clinic, University Hospital Zürich, CH-8091 Zürich, Switzerland (telephone: +41-44-255-9616; FAX: +41-44-255-4566)
    • Nothing to disclose.
  • ,
  • Pierre-Guy Chassot

      Affiliations

    • Department of Biology and Medicine, University Hospital Lausanne, Lausanne, Switzerland
    • Nothing to disclose.
  • ,
  • Tullio Sulser

      Affiliations

    • Urology Clinic, University Hospital Zürich, Zürich, Switzerland
    • Nothing to disclose.
  • ,
  • Charles Marc Samama

      Affiliations

    • Department of Anaesthesiology and Intensive Care, Hotel-Dieu University Hospital, Paris, France
    • Nothing to disclose.
  • ,
  • Jean Mantz

      Affiliations

    • Department of Anaesthesiology and Critical Care, Beaujon & Louis Mourier University Hospitals, Clichy, France
    • Nothing to disclose.
  • ,
  • Alain Delabays

      Affiliations

    • Department of Cardiology, University Hospital Lausanne, Lausanne, Switzerland
    • Nothing to disclose.
  • ,
  • Donat R. Spahn

      Affiliations

    • Institute of Anaesthesiology, University Hospital Zürich, Zürich, Switzerland
    • Financial interest and/or other relationship with Abbot, Alliance Pharmaceutical Corp., AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Fresenius, Galencia, GlaxoSmithKline, Janssen-Cilag, Novo Nordisk, Octapharma, Organon, Pentapharm, Roche Pharma and Schering-Plough International.

Received 26 August 2009

  • Image Result

    Incidence of major adverse cardiac events (MACE) according to delay (months) between stent implantation and noncardiac surgery. Events include MI, stent thrombosis, target vessel revascularization and

    Incidence of major adverse cardiac events (MACE) according to delay (months) between stent implantation and noncardiac surgery. Events include MI, stent thrombosis, target vessel revascularization and death.

  • Image Result
    Mortality of patients with coronary stents taken off AP drugs for noncardiac surgery according to delay since coronary revascularization (Artang R: Am J Cardiol 2007; 99: 1039; Brotman DJ: J Hosp Med

    Mortality of patients with coronary stents taken off AP drugs for noncardiac surgery according to delay since coronary revascularization (Artang R: Am J Cardiol 2007; 99: 1039; Brotman DJ: J Hosp Med 2007; 2: 378; Rhee SJ: Int Heart J 2008; 49: 135; Kim HL: Int J Cardiol 2008; 123: 353). Two studies have comparative data on mortality of patients operated on without cessation of AP drugs (5% and 0%, respectively).

  • Image Result
    Algorithm for preoperative treatment of patients on AP therapy adapted and updated from Chassot et al.40 1 Aspirin given after previous event (MI, ACS, PCI and stent, CABG, peripheral arterial disease

    Algorithm for preoperative treatment of patients on AP therapy adapted and updated from Chassot et al.40 1 Aspirin given after previous event (MI, ACS, PCI and stent, CABG, peripheral arterial disease and stroke) or for documented cardiovascular disease, and high risk patients include diabetics and those with multiple risk factors. 2 Multiple stents, long stents, proximal location (left main) and bifurcation lesions, and patients with previous stent thrombosis. 3 Operations mandatory for long-term survival. Recommended delay between drug interruption and surgery is 5 days for aspirin and clopidogrel. 4 Risk-to-benefit ratio of maintaining vs withdrawing aspirin, clopidogrel and prasugrel must be evaluated for each case, and withdrawing postoperative reinstitution (with clopidogrel loading dose 300 mg) within 24 hours is important. 5 Stop clopidogrel for 5 days and substitute with 3 to 5 days of intravenous perfusion of eptifibatide or tirofiban. SCA, sudden cardiac arrest.

  • Image Result
    Algorithm of strategies to decrease risk of stent thrombosis in case of coronary revascularization and urgent or semi-urgent noncardiac surgery. Asterisk indicates except in closed space surgery (intr

    Algorithm of strategies to decrease risk of stent thrombosis in case of coronary revascularization and urgent or semi-urgent noncardiac surgery. Asterisk indicates except in closed space surgery (intracranial neurosurgery, surgery of medullary canal, surgery of posterior chamber of eye), and invasive surgery with severe bleeding and difficult hemostasis.

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2474 and 2475.

PII: S0022-5347(10)02661-3

doi: 10.1016/j.juro.2010.02.2391

The Journal of Urology
Volume 183, Issue 6 , Pages 2128-2136 , June 2010